Mitoxantrone as a substitute for daunorubicin during induction in newly diagnosed lymphoblastic leukemia and lymphoma-Reference-Cited by-同舟云学术

Mitoxantrone as a substitute for daunorubicin during induction in newly diagnosed lymphoblastic leukemia and lymphoma

Author:

Nickel Robert S.¹,Keller Frank¹,Bergsagel John¹,Cooper Todd¹,Daves Marla¹,Sabnis Himalee¹,Lew Glen

Affiliation:

1. Aflac Cancer and Blood Disorders Center; Children's Healthcare of Atlanta; Emory University; Atlanta Georgia

Funder

National Center for Advancing Translational Sciences of the National Institutes of Health

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

Reference23 articles.

1. Comparison of the antileukemic effect in mice of adramycin with daunomycin;Sandberg;Cancer Chemother Rep,1970

2. Adriamycin and daunorubicin: A comparison of antitumor activities and tissue uptake in mice following immunosuppression;Schwartz;Cancer Res,1973

3. Cytotoxicity of adriamycin and daunorubicin for normal and leukemia progenitor cells of man;Buick;J Natl Cancer Inst,1979

4. Comparative biochemical studies of adriamycin and daunomycin in leukemic cells;Wang;Cancer Res,1972

5. In vitro cytotoxicity of mitoxantrone, daunorubicin and doxorubicin in untreated childhood acute leukemia;Kaspers;Leukemia,1994

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献